The ESMO 2026 Annual Meeting will be held Oct 23 to 27, 2026, in Madrid, Spain. On Oct 19, ESMO released a first set of abstracts. The studies below cover lung cancer and other thoracic malignancies.
Late-breaking abstracts (LBAs) have not yet been announced and will be presented during the meeting.
All six studies below were released as conference abstracts and had not yet been peer-reviewed at the time of this report.
Article Key Points
- Meeting: ESMO 2026, Oct 23-27, 2026, Madrid; latest breaking abstracts not yet released
- Dalmelitinib plus aumolertinib, phase 3, n=314: IRC PFS 6.2 vs 4.4 months (HR 0.601), ORR 59.6% vs 38.6%
- OS immature at data cutoff; chemotherapy arm 46.8% crossed over
- CS2009 (PD-1/VEGF/CTLA-4 trispecific), phase 2, n=86: first-line monotherapy ORR 81.3% in PD-L1 TPS>=50% (n=16)
- BAT8008 (TROP2 ADC, DAR~6) plus BAT1308, phase 2, n=97: ORR 57.9%, DCR 89.5%, 6-month PFS 64.8%
- SKB500 (B7-H3 ADC) in ES-SCLC, phase 1, n=61: ORR 67.2%, median PFS 7.2 months; 12 mg/kg better tolerated
- LungMate-014 phase 2, n=118: pCR 32.2% vs 25.4%; 24-month EFS 71.1% vs 66.0% at 26.6-month follow-up
- iTHYM phase 2, n=24: ORR 83.3%, DCR 100%; the 6-month PFS endpoint was met with longer follow-up needed
- Evidence status: conference abstracts; several datasets are preliminary and full results have not yet been peer-reviewed
Abstract 2615O
Dalmelitinib Plus Aumolertinib Versus Platinum-Based Chemotherapy in Advanced NSCLC Patients with MET Amplification Post EGFR TKI: A Randomized, Phase 3 Study
Presenter: Ziming Li, Shanghai Pulmonary Hospital
This randomized, open, multicenter phase 3 study enrolled advanced NSCLC patients with EGFR mutation and MET amplification (GCN of at least 5 or MET/CEP7 of at least 2) who had progressed after EGFR tyrosine kinase inhibitor (TKI) therapy. Patients were randomized 1:1 to dalmelitinib plus aumolertinib (combination arm) or platinum-based chemotherapy (chemotherapy arm). The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC).
As of Dec 10, 2025, 314 patients had been randomized (156 in the combination arm and 158 in the chemotherapy arm), and 94.3% had previously received a third-generation EGFR TKI.
The combination arm significantly improved PFS over chemotherapy: median PFS by IRC assessment was 6.2 vs 4.4 months (HR 0.601, P<0.001), and by investigator assessment was 6.9 vs 4.6 months. Objective response rate (ORR) was 59.6% vs 38.6%, median duration of response (DoR) was 9.7 vs 4.4 months, and disease control rate (DCR) was 84.6% vs 74.1%. Preliminary overall survival (OS) data showed a trend toward benefit (not reached vs 19.6 months, HR 0.840; 46.8% of the chemotherapy arm crossed over).
For safety, grade 3 or higher treatment-emergent adverse events occurred in 50.0% vs 51.0%. Common events in the combination arm were elevated liver enzymes, mostly low grade, reversible, and manageable.
The results suggest that dalmelitinib plus aumolertinib is superior to chemotherapy in EGFR mutation-positive, MET-amplified patients with MET amplification of at least 5 copies, most of whom had progressed on third-generation EGFR TKIs, and provides a new treatment option for this population.
Abstract 2616RO
A Phase 2 Study of CS2009, a First-in-Class PD-1/VEGF/CTLA-4 Trispecific Antibody, in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Anwen Xiong, East Hospital affiliated to Tongji University
CS2009 is a novel PD-1/VEGF/CTLA-4 trispecific antibody that has shown antitumor activity in preclinical and clinical studies. This report presents phase 2 safety and efficacy data for CS2009 in advanced NSCLC.
The study enrolled advanced NSCLC patients across different lines of therapy. First-line patients without an actionable mutation received CS2009 monotherapy or in combination with chemotherapy (non-squamous: pemetrexed plus carboplatin; squamous: paclitaxel plus carboplatin). Second- or third-line patients previously treated with platinum chemotherapy and anti-PD-(L)1 therapy received CS2009 plus docetaxel. CS2009 was administered at 20 or 30 mg/kg every 3 weeks. The primary endpoint was investigator-assessed ORR.
As of April 19, 2026, 86 patients had been treated, with a median age of 65.6 years, 77.9% male, 82.6% with ECOG PS of 1, and 40.7% with non-squamous histology. A total of 76.7% had PD-L1 TPS of at least 1%.
In the monotherapy group (n=46), any-grade and grade 3 or higher treatment-related adverse events occurred in 67.4% and 6.5% respectively. The most common were AST elevation (17.4%), ALT elevation (15.2%), hyperthyroidism (13.0%), and rash (13.0%); all grade 3 or higher events were single instances. In the chemotherapy combination group (n=40), the corresponding rates were 65.0% and 30.0%, most commonly neutropenia (35.0%), leukopenia (30.0%), and anemia (30.0%). CS2009 did not markedly increase chemotherapy toxicity, and no unexpected safety signal was seen.
Preliminary efficacy in first-line monotherapy patients with PD-L1 TPS of at least 50% showed ORR and DCR of 81.3% and 100% (n=16). First-line squamous combination in patients with PD-L1 TPS below 50% showed 75.0% and 100% (n=8). Encouraging responses were observed in other cohorts as well; updated data will be presented at the meeting.
Abstract 2631RO
First-Line BAT8008 (TROP2-ADC) Plus BAT1308 (Anti-PD-1) for Advanced NSCLC: Results from a Multicenter Phase 2 Study
Presenter: Shaodong Hong, Sun Yat-sen University Cancer Center
BAT8008 is a novel TROP2 antibody-drug conjugate with an exatecan payload, using a stable, cleavable PEG8 linker and a drug-to-antibody ratio (DAR) of approximately 6, designed to widen the therapeutic window. TROP2 ADCs combined with immunotherapy are being explored in first-line advanced NSCLC, but myelosuppression and stomatitis remain tolerability concerns. This study reports preliminary efficacy and safety of BAT8008 combined with the anti-PD-1 antibody BAT1308 in first-line NSCLC.
This multicenter, open-label, single-arm phase 2 study enrolled treatment-naive advanced NSCLC patients who received BAT8008 2.4 mg/kg plus BAT1308 200 mg intravenously every 2 weeks. The primary endpoints were safety and ORR.
As of April 28, 2026, 97 patients had been enrolled, with a median age of 64 years, 53.6% with squamous histology, and 89% with ECOG PS of 1. Treatment-related adverse events occurred in 87.6%, with 38.1% at grade 3 or higher. Despite the relatively high DAR, severe stomatitis and hematologic toxicity were relatively uncommon: anemia 7.2%, stomatitis 7.2%, leukopenia 14.4%, and neutropenia 15.5%. No new immune-related safety signal was observed.
Among 76 evaluable patients, ORR was 57.9%, DCR was 89.5%, and the 6-month PFS rate was 64.8%. Antitumor activity was observed across PD-L1 subgroups and histologies.
The results suggest that BAT8008 plus BAT1308 shows clinically meaningful activity in advanced NSCLC with manageable toxicity, supporting subsequent randomized studies, and indicate that this regimen may offer a favorable activity-toxicity balance suitable for long-term first-line combination therapy.
Abstract 3816RO
SKB500 (A Novel B7-H3-Targeted Antibody-Drug Conjugate) in Patients with Extensive-Stage Small Cell Lung Cancer: Results from a Phase I Study
Presenter: Haifeng Liu, Jilin Cancer Hospital
SKB500 is an ADC targeting B7-H3, consisting of an antibody conjugated through a cleavable pyrimidine-tripeptide linker to a topoisomerase I inhibitor payload. This study reports updated safety and antitumor activity for SKB500 in small cell lung cancer (SCLC).
This multicenter, open-label phase 1 study enrolled heavily pretreated, unresectable SCLC patients. Expansion cohorts received SKB500 at 12 or 16 mg/kg every 3 weeks. The primary efficacy endpoint was investigator-assessed ORR.
As of April 20, 2026, 61 patients had received treatment and been followed for at least 6 weeks (40 at 12 mg/kg and 21 at 16 mg/kg), with median follow-up of 4.6 months. All patients had received platinum-based therapy, and 85.2% had previously received anti-PD-(L)1 therapy.
ORR was 67.2% (70.0% in the 12 mg/kg group vs 61.9% in the 16 mg/kg group), median DoR was 5.8 months, and median PFS was 7.2 months. B7-H3 expression showed no significant predictive value, with preliminary indications that SLFN11 levels may be associated with response.
For safety, grade 3 or higher treatment-related adverse events were less frequent in the 12 mg/kg group (47.5% vs 61.9%), most commonly leukopenia, lymphopenia, thrombocytopenia, and anemia.
The results suggest that SKB500 at 12 mg/kg offers a better safety and activity profile than 16 mg/kg, supporting further clinical development.
Abstract 2574RO
Neoadjuvant Toripalimab Plus Chemotherapy with or without Tifcemalimab (Anti-BTLA Antibody) in Potentially Resectable Stage III Non-Small Cell Lung Cancer (LungMate-014): A Randomized, Phase II Trial
Presenter: Peng Zhang
Perioperative toripalimab plus chemotherapy has been shown to improve outcomes in patients with resectable stage III NSCLC, and tifcemalimab combined with toripalimab has demonstrated activity in advanced disease. This study is the first to evaluate the addition of tifcemalimab, an anti-BTLA antibody, to neoadjuvant toripalimab plus chemotherapy.
This open-label, single-center phase 2 study randomized patients with potentially resectable stage III NSCLC 1:1 to tifcemalimab plus toripalimab plus chemotherapy (TCT arm) or the same regimen without tifcemalimab (TC arm) for 4 cycles. The primary endpoint was pathological complete response (pCR) rate.
As of Aug 29, 2024, 118 patients had been enrolled. The pCR rates in the TCT and TC arms were 32.2% and 25.4% respectively, and were higher in the non-squamous (31.6% vs 15.0%) and PD-L1 TPS below 1% (35.7% vs 25.9%) subgroups. The surgery rate was 67.8% vs 59.3%, and R0 resection was achieved in all cases. Grade 3 or higher treatment-related adverse events occurred in 77.6% vs 75.4%, with no new safety signal.
With a median follow-up of 26.6 months, 24-month event-free survival (EFS) was 71.1% vs 66.0%, and OS was 83.0% vs 76.1%. In non-squamous disease, OS was 89.5% vs 79.4%; in patients with PD-L1 TPS below 1%, it was 88.1% vs 69.6%.
The results suggest the TCT regimen has encouraging efficacy and manageable safety, with clearer benefit in patients with non-squamous histology and PD-L1 TPS below 1%, supporting larger randomized studies.
Abstract 4156RO
Ivonescimab Plus Chemotherapy as First-Line Treatment in Recurrent/Metastatic Thymic Carcinoma: Interim Results from the iTHYM Phase II Study
Presenter: Xue Hou, Sun Yat-sen University Cancer Center
iTHYM is a prospective, multicenter, single-arm phase 2 study evaluating the PD-1/VEGF bispecific antibody ivonescimab combined with carboplatin plus paclitaxel or nab-paclitaxel as first-line treatment in recurrent or metastatic thymic carcinoma, followed by ivonescimab maintenance. The primary endpoint was the 6-month progression-free survival rate (PFS6m).
As of July 31, 2026, 24 patients had been enrolled and treated. Twenty patients achieved partial response and four had stable disease, giving an ORR of 83.3% and a DCR of 100%. All 19 evaluable patients for the primary endpoint were progression-free at 6 months, and the study met its prespecified PFS6m endpoint.
With a median follow-up of 10.2 months, four patients had progressed, at 7.0, 8.1, 10.8, and 18.2 months respectively. Median PFS and OS were not reached. Safety was manageable, with hematologic toxicity mainly related to chemotherapy. Ivonescimab-related adverse events were mostly low grade, including bleeding 37.5%, rash or pruritus 33.3%, and proteinuria 12.5%; grade 3 proteinuria occurred in 8.3%, and grade 3 acute coronary syndrome in 4.2% led to permanent discontinuation.
The results suggest that ivonescimab plus a taxane and carboplatin as first-line treatment for recurrent or metastatic thymic carcinoma has encouraging efficacy and manageable safety, and met its primary endpoint. Longer follow-up is needed to determine the final PFS6m and long-term benefit.
Closing Note
This preview covers a selection of lung and thoracic oncology abstracts from Chinese investigators. Additional reports from the ESMO 2026 meeting will be covered during the meeting itself.
Evidence status: all studies described here were released as conference abstracts ahead of the meeting. Several datasets are preliminary by the investigators’ own description, latest breaking abstracts had not been announced at the time of this report, and full results have not yet been peer-reviewed.